research use only
Cat.No.E1993
| Related Targets | EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R HER2 FLT3 |
|---|---|
| Other BTK Inhibitors | Spebrutinib (AVL-292) tirabrutinib(ONO-4059) hydrochloride LFM-A13 CGI1746 Evobrutinib BMS-935177 CNX-774 Branebrutinib (BMS-986195) Fenebrutinib (GDC-0853) Pirtobrutinib (LOXO-305) |
|
In vitro |
DMSO
: 100 mg/mL
(117.5 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about Catadegbrutinib (BGB-16673) solubility in DMSO or water
Read more about Catadegbrutinib (BGB-16673) working concentrations for cell culture treatment
Catadegbrutinib (BGB-16673) is a potent inhibitor of BTK (0.69 ± 0.091 nM), CRBN-DBB1 complex (316 ± 82 nM). Catadegbrutinib (BGB-16673) exhibits the greatest inhibitory potency toward BTK (IC50 = 0.69 ± 0.091 nM).
| Information | Catadegbrutinib (BGB-16673) is a potent, highly selective BTK targeted protein degrader. It affects B-cell receptor (BCR) signaling by inducing the ubiquitination and proteasomal degradation of wild-type and mutant BTK, effectively inhibiting B-cell proliferation and tumor growth in B-cell malignancies. |
|---|---|
|
Read more about Catadegbrutinib (BGB-16673) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
Read more about Catadegbrutinib (BGB-16673) Mechanism of Action
| Molecular Weight | 851.01 | Formula | C47H54N12O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2736508-60-2 | Download SDF | Storage of Stock Solutions |
|
|
Read more comparative analysis about Catadegbrutinib (BGB-16673)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.